ClinConnect ClinConnect Logo
Search / Trial NCT06912425

Effects of an Exercise and Diet Program on Biochemistry and Body Composition in Patients With CKD in G1 and G2 Stages

Launched by UNIVERSITY OF GUADALAJARA · Mar 30, 2025

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Health Belief Model Kidney Chronic Disease Exercise Diet

ClinConnect Summary

This clinical trial is exploring how a combination of exercise, a controlled diet, and educational support can improve the health of people with early-stage kidney disease (specifically stages G1 and G2). The goal is to see if these lifestyle changes can help improve their body composition and overall health. The study is being conducted at Ciudad Guzmán Hospital and is currently looking for participants aged 18 to 65 who have been diagnosed with chronic kidney disease. To be eligible, individuals must have specific kidney function levels, stable blood pressure, and must be able to safely participate in exercise.

Participants in this study can expect to receive guidance on exercise routines and nutrition, along with educational resources about managing their health. This will help them make positive changes in their daily lives. Even those who might not have access to technology will receive materials to support their participation. It's important to note that individuals with more advanced kidney disease or certain health conditions, such as uncontrolled diabetes or severe blood pressure issues, will not be eligible for this study. If you or someone you know is interested and meets the criteria, this could be a valuable opportunity to improve health and well-being.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Established diagnosis of CKD by the physician in G1 and G2
  • * Who meet the requirements of normal or decreased filtration rate according to:
  • G1: ≥ 90 or G2: 60-89 mL/ min/ 1.73m2
  • Alterations in the urinary sediment (cellular cylinders of any type, dysmorphic erythrocytes).
  • Confirmation of damage by renal ultrasound (Decreased renal size, thinning of the renal cortex, increased echogenicity of the parenchyma, poor differentiation between the renal cortex and sinus, renal cysts suggestive of cortical or medullary changes).
  • Men and women between 18 and 65 years old
  • Control of baseline pathologies (glycosylated hemoglobin less than 9%, blood pressure no higher than 140/90mmHg).
  • Patients who agree to participate in the study and sign the informed consent form.
  • Patients who have no limitations to perform the exercises.
  • If participants have diagnosed diabetes or hypertension, who are on medication and under regular internal medicine or nephrology treatment.
  • Male and female patients, including those who are illiterate but can be accompanied in the initial sessions to sign the informed consent form.
  • All participants, even those who do not have a mobile device, will be provided with an exercise and nutrition guide so that they do not have any limitations when carrying out the activities.
  • Exclusion Criteria:
  • Stages 3, 4 and 5
  • Children under 18 years of age
  • Patients who, due to their place of origin, find it difficult to travel to the sessions.
  • Diabetes Mellitus in uncontrolled (Glycated Hemoglobin \>9 %)
  • Those who have lost their sight
  • Presence of uremic alterations such as uremic encephalopathy.
  • Who present unstable blood pressure with blood pressure levels above 140/90mmHg, patients showing sustained blood pressure elevations above 140/90 will be discontinued from the study.
  • Peripheral vascular disease of all types (Peripheral Arterial Disease (PAD), Deep Vein Thrombosis (DVT), Chronic Venous Disease (CVD), Abdominal Aortic Aneurysm (AAA), Buerger's Phenomenon (Thromboangiitis Obliterans), Kawasaki Disease).
  • Failure to sign the informed consent form
  • Elimination Criteria:
  • Injury, discomfort that makes reincorporation impossible.
  • Patients who have decided to abandon the study
  • Patients who do not attend 2 of the face-to-face sessions, those who do not attend two of their sessions will be taken into consideration.

About University Of Guadalajara

The University of Guadalajara, a prominent academic institution in Mexico, is dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a commitment to scientific excellence and ethical standards, the university collaborates with various stakeholders to conduct rigorous studies aimed at addressing critical health challenges. Its multidisciplinary approach harnesses the expertise of faculty and researchers across diverse fields, fostering a robust environment for the development of groundbreaking treatments and interventions. By actively contributing to the global body of medical knowledge, the University of Guadalajara plays a vital role in enhancing patient care and promoting public health initiatives.

Locations

Ciudad Guzmán, Jalisco, Mexico

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported